Effects of imatinib on glycemic and lipid profiles: a retrospective cohort study

References

• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018;93(3):442–459.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Makenbaeva D, Lingohr-Smith M, et al. Use of real-world claim databases to assess prevalence of comorbid conditions relevant to the treatment of chronic myelogenous leukemia based on National Comprehensive Network Treatment Guidelines. Clin Lymphoma Myeloma Leuk. 2015;15(12):797–802.
   PubMed Web of Science ®Google Scholar
• Raut CP, Espat NJ, Maki RG, et al. Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate- or high-risk primary gastrointestinal stromal tumor: the PERSIST-5 clinical trial. JAMA Oncol. 2018;4(12):e184060.
   PubMed Web of Science ®Google Scholar
• Balachandran VP, DeMatteo RP. Gastrointestinal stromal tumors: who should get imatinib and for how long? Adv Surg. 2014;48(1):165–183.
   PubMedGoogle Scholar
• Buffier P, Bouillet B, Smati S, et al. Expert opinion on the metabolic complications of new anticancer therapies: tyrosine kinase inhibitors. Ann Endocrinol. 2018;79(5):574–582.
   PubMed Web of Science ®Google Scholar
• Malek R, Davis SN. Tyrosine kinase inhibitors under investigation for the treatment of type II diabetes. Expert Opin Investig Drugs. 2016;25(3):287–296.
   PubMed Web of Science ®Google Scholar
• Agostino NM, Chinchilli VM, Lynch CJ, et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract. 2011;17(3):197–202.
   PubMedGoogle Scholar
• Breccia M, Muscaritoli M, Aversa Z, et al. Imatinib mesylate may improve fasting blood glucose in diabetic Ph + chronic myelogenous leukemia patients responsive to treatment. J Clin Oncol. 2004;22(22):4653–4655.
   PubMed Web of Science ®Google Scholar
• Veneri D, Franchini M, Bonora E. Imatinib and regression of type 2 diabetes. N Engl J Med. 2005;352(10):1049–1050.
   PubMed Web of Science ®Google Scholar
• Breccia M, Muscaritoli M, Alimena G. Reduction of glycosylated hemoglobin with stable insulin levels in a diabetic patient with chronic myeloid leukemia responsive to imatinib. Haematologica. 2005;90(Suppl.):ECR21.
   PubMedGoogle Scholar
• Gómez-Sámano MÁ, Baquerizo-Burgos JE, Coronel MFC, et al. Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor. BMC Endocr Disord. 2018;18(1):77.
   PubMedGoogle Scholar
• Dingli D, Wolf RC, Vella A. Imatinib and type 2 diabetes. Endocr Pract. 2007;13(2):126–130.
   PubMedGoogle Scholar
• Mariani S, Tornaghi L, Sassone M, et al. Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia. Leuk Res. 2010;34(1):e5–e7.
   PubMed Web of Science ®Google Scholar
• Ashry NA, Abdеlaziz RR, Suddеk GM. The potential effect of imatinib against hypercholesterolemia induced atherosclerosis, endothelial dysfunction and hepatic injury in rabbits. Life Sci. 2020;243:117275.
   PubMed Web of Science ®Google Scholar
• Ellis M, Krashin E, Hamburger-Avnery O, et al. The anti-leukemic and lipid lowering effects of imatinib are not hindered by statins in CML: a retrospective clinical study and in vitro assessment of lipid-genes transcription. Leuk Lymphoma. 2017;58(5):1172–1177.
   PubMed Web of Science ®Google Scholar
• Horňák T, Semerád L, Žáčková D, et al. Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients – results from real-life prospective study. Leuk Lymphoma. 2020;61(2):494–496.
   PubMed Web of Science ®Google Scholar
• Franceschino A, Tornaghi L, Benemacher V, et al. Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib. Haematologica. 2008;93(2):317–318.
   PubMed Web of Science ®Google Scholar
• Gottardi M, Manzato E, Gherlinzoni F. Imatinib and hyperlipidemia. N Engl J Med. 2005;353(25):2722–2723.
   PubMed Web of Science ®Google Scholar
• Shalev V, Chodick G, Silber H, et al. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med. 2009;169(3):260–268.
   PubMedGoogle Scholar
• Sherifali D, Nerenberg K, Pullenayegum E, et al. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care. 2010;33(8):1859–1864.
   PubMedGoogle Scholar
• Chaudhury A, Duvoor C, Reddy Dendi VS, et al. Clinical review of antidiabetic drugs: implications for type 2. Front Endocrinol. 2017;8:6.
   PubMed Web of Science ®Google Scholar
• Levine MJ. Empagliflozin for type 2 diabetes mellitus: an overview of phase 3 clinical trials. Curr Diabetes Rev. 2017;13(4):405–423.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Stonehouse AH, Han J, et al. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med. 2010;27(3):309–317.
   PubMed Web of Science ®Google Scholar
• Pouwer MG, Pieterman EJ, Verschuren L, et al. The BCR-ABL1 inhibitors imatinib and ponatinib decrease plasma cholesterol and atherosclerosis, and nilotinib and ponatinib activate coagulation in a translational mouse model. Front Cardiovasc Med. 2018;5:55.
   PubMed Web of Science ®Google Scholar
• Breccia M, Muscaritoli M, Gentilini F, et al. Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. Leuk Res. 2007;31(12):1770–1772.
   PubMed Web of Science ®Google Scholar
• Ismail AS, Yassin MA. Nilotinib-Induced diabetes mellitus in a young female with chronic myeloid leukemia. Cureus. 2020;12(9):e10277.
   PubMed Web of Science ®Google Scholar
• Ito Y, Miyamoto T, Chong Y, et al. Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin. Int J Hematol. 2013;97(1):135–138.
   PubMed Web of Science ®Google Scholar
• Okada N, Niimura T, Zamami Y, et al. Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database. Cancer Med. 2019;8(1):174–181.
   PubMed Web of Science ®Google Scholar
• Rea D, Mirault T, Cluzeau T, et al. Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica. 2014;99(7):1197–1203.
   PubMed Web of Science ®Google Scholar
• Breccia M, Muscaritoli M, Cannella L, et al. Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk Res. 2008;32(10):1626–1628.
   PubMed Web of Science ®Google Scholar
• Ono K, Suzushima H, Watanabe Y, et al. Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus. Intern Med. 2012;51(19):2763–2766.
   PubMed Web of Science ®Google Scholar
• Iizuka K, Niwa H, Kato T, et al. Dasatinib improves insulin sensitivity and affects lipid metabolism in a patient with chronic myeloid leukaemia. BMJ Case Rep. 2016;2016:bcr2015214284.
   PubMedGoogle Scholar
• Kaehler M, Cascorbi I. Pharmacogenomics of impaired tyrosine kinase inhibitor response: lessons learned from chronic myelogenous leukemia. Front Pharmacol. 2021;12:696960.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–1054.
   PubMed Web of Science ®Google Scholar
• Breccia M, Molica M, Zacheo I, et al. Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment. Ann Hematol. 2015;94(3):393–397.
   PubMed Web of Science ®Google Scholar
• Martino B, Mammi C, Labate C, et al. Genetic risk of prediabetes and diabetes development in chronic myeloid leukemia patients treated with nilotinib. Exp Hematol. 2017;55:71–75.
   PubMed Web of Science ®Google Scholar